首页> 美国卫生研究院文献>The Journal of Biological Chemistry >A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties
【2h】

A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties

机译:一种新型糖工程双特异性抗体形式可选择性抑制表皮生长因子受体(EGFR)和I型胰岛素样生长因子受体(IGF-1R)表现出独特的分子特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the present study, we have developed a novel one-arm single chain Fab heterodimeric bispecific IgG (OAscFab-IgG) antibody format targeting the insulin-like growth factor receptor type I (IGF-1R) and the epidermal growth factor receptor (EGFR) with one binding site for each target antigen. The bispecific antibody XGFR is based on the “knob-into-hole” technology for heavy chain heterodimerization with one heavy chain consisting of a single chain Fab to prevent wrong pairing of light chains. XGFR was produced with high expression yields and showed simultaneous binding to IGF-1R and EGFR with high affinity. Due to monovalent binding of XGFR to IGF-1R, IGF-1R internalization was strongly reduced compared with the bivalent parental antibody, leading to enhanced Fc-mediated cellular cytotoxicity. To further increase immune effector functions triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted in strong antibody-dependent cell-mediated cytotoxicity activity. XGFR-mediated inhibition of IGF-1R and EGFR phosphorylation as well as A549 tumor cell proliferation was highly effective and was comparable with a combined treatment with EGFR (GA201) and IGF-1R (R1507) antibodies. XGFR also demonstrated potent anti-tumor efficacy in multiple mouse xenograft tumor models with a complete growth inhibition of AsPC1 human pancreatic tumors and improved survival of SCID beige mice carrying A549 human lung tumors compared with treatment with antibodies targeting either IGF-1R or EGFR. In summary, we have applied rational antibody engineering technology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inhibition with antibody-dependent cell-mediated cytotoxicity induction and results in superior molecular properties over two established tetravalent bispecific formats.
机译:在本研究中,我们已经开发了针对I型胰岛素样生长因子受体(IGF-1R)和表皮生长因子受体(EGFR)的新型单臂单链Fab异二聚体双特异性IgG(OAscFab-IgG)抗体形式每个靶抗原具有一个结合位点。双特异性抗体XGFR基于“旋钮插入孔”技术,用于重链异二聚化,其中一条重链由单链Fab组成,可防止轻链错误配对。 XGFR以高表达产量生产,并以高亲和力同时与IGF-1R和EGFR结合。由于XGFR与IGF-1R的单价结合,与二价亲本抗体相比,IGF-1R的内在化作用大大降低,从而导致Fc介导的细胞毒性增强。为了进一步增加由XGFR触发的免疫效应子功能,对双特异性抗体的Fc部分进行了糖工程改造,从而产生了强大的抗体依赖性细胞介导的细胞毒性活性。 XGFR介导的对IGF-1R和EGFR磷酸化以及A549肿瘤细胞增殖的抑制作用非常有效,并且与EGFR(GA201)和IGF-1R(R1507)抗体的联合治疗相当。与靶向IGF-1R或EGFR的抗体治疗相比,XGFR还显示出在多种小鼠异种移植肿瘤模型中的强效抗肿瘤功效,完全抑制了AsPC1人胰腺肿瘤的生长,并提高了携带A549人肺肿瘤的SCID米色小鼠的存活率。总而言之,我们已经应用合理的抗体工程技术来开发异二聚体OAscFab-IgG双特异性抗体,该抗体将有效的信号抑制与抗体依赖性细胞介导的细胞毒性诱导相结合,并且在两种已建立的四价双特异性形式上均具有优异的分子特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号